



Advancing a Diversified Clinical Pipeline



OUT-LICENSED



■ HPV-RELATED DISEASES
 ■ IMMUNO-ONCOLOGY
 ■ INFECTIOUS DISEASES
 ■ VARIOUS DISEASE TARGETS

*BLA accepted for review under accelerated approval program in Dec 2025 with a target PDUFA date of Oct 2026 **VGX-3100 to Apollo Bio for China